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Abstract
Background: The genus Chromobacterium consists of 7 recognized species. Among those, only C. violaceum,
commonly found in the soil and water of tropical and subtropical regions, has been shown to cause human
infection. Although human infection is rare, C. violaceum can cause life-threatening sepsis, with metastatic
abscesses, most frequently infecting those who are young and healthy.
Case presentation: We recently identified a case of severe bacteremia caused by Chromobacterium haemolyticum
infection in a healthy young patient following trauma and exposure to river water, in Japan. The patient developed
necrotizing fasciitis that was successfully treated with a fasciotomy and intravenous ciprofloxacin and gentamicin.
Conclusions: C. haemolyticum should be considered in the differential diagnosis of skin lesions that progressively
worsen after trauma involving exposure to river or lake water, even in temperate regions. Second, early blood
cultures for the isolation and identification of the causative organism were important for initiating proper
antimicrobial therapy.
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Background
The genus Chromobacterium consists of 7 recognized
species: C. violaceum, C. subtsugae, C. aquaticum, C.
haemolyticum, C. pseudoviolaceum, C. piscinae [1], and C.
vaccinii [2]. Of these species, only C. violaceum, commonly
found in the soil and water of tropical and subtropical
regions, has been shown to cause human infection. Al-
though human infection is rare, C. violaceum can cause
life-threatening sepsis, with metastatic abscesses, most
frequently infecting those who are young and healthy [3].
We describe, here, clinical evidence for another species,
C. haemolyticum, which caused an infection in a healthy,
young patient. This bacterium should be considered in the
differential diagnosis of skin lesions that quickly worsen
after trauma associated with exposure to river or lake
water. This is particularly important because of the
species’ resistance to antimicrobials, particularly β-lactams.
Case presentation
A healthy, 26-year-old Japanese man was admitted to
our hospital with pain in his left shoulder and leg caused
by a road accident; he was hit by a car and thrown into
a river. The outside air and water temperatures at the
time of the injury were 20°C. He had no family history
of any particular condition.
Upon admission, his temperature was 36.6°C; pulse rate,
66 beats/min; blood pressure, 143/99 mmHg; respiratory
rate, 15/min; oxygen saturation, 100% (10-L reservoir
mask); and Glasgow Coma Scale score, E4V5M6. A
physical examination showed only bruising, not open
wounds, on the left side of his face and shoulder and
tenderness in his left leg. His height, weight, and body
mass index were 175 cm, 67 kg, and 21.9 kg/m2,
respectively. Laboratory tests showed mild inflammation
(white blood cell [WBC] count, 13,500/μL; and C-reactive
protein [CRP], 0.9 mg/L [normal range: < 2.0 mg/L]). A
radiograph showed fractures of the fibula shaft and
scapula.
On post-admission day 3, the patient exhibited a
temperature of 40°C, shivering, and redness and pain in
his ankle. Intravenous ampicillin/sulbactam (6 g/day)
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and minocycline (200 mg/day) were initiated. However,
on the fourth day of admission, the antimicrobial drugs
were changed to ceftazidime at 4 g/day, as 2 sets of
blood culture tests revealed gram-negative bacilli. Until
then, the redness in his ankle had not expanded. On
day 5, the erythematous, warmth and pain spread to his
knee joint, and blisters were observed on the upper
part of his foot (Figure 1). The patient was diagnosed
with necrotizing fasciitis and a fasciotomy was conducted.
The underlying muscle appeared healthy, and further
debridement was avoided. The pathology of the dorsum
of his left foot revealed inflamed skin and soft tissue,
with necrosis consistent with necrotizing fasciitis. La-
boratory tests showed an inflammatory reaction (WBC
count, 13,500/μL; CRP, 196.3 mg/L), and hyperglycemia
(192 mg/dL). Thus, the Laboratory Risk Indicator for
Necrotizing Fasciitis (LRINEC) score [4] was 6 (intermedi-
ate risk). The smear from the fasciotomy site and blood
culture tests revealed gram-negative bacilli (Figure 2A),
and the infecting bacterium was oxidase-positive and
produced grey colonies, with a 4.3-mm hemolytic zone
on sheep blood-agar plates (Figure 2B); non-pigmented
colonies were found on bromothymol-blue lactose agar
plates, suggesting that C. haemolyticum was the causative
agent. However, the Vitek GNI + card (bioMérieux Vitek,
Hazelwood, MO, USA) and the API 20 NE test
(bioMérieux Vitek) identified the organism as C.
violaceum. The antibiotics were changed to intravenous
ciprofloxacin (900 mg/day) and gentamicin (400 mg/
day [6 mg · kg-1 · day-1]). This antimicrobial regimen
was continued for 28 days. After that, gentamicin was
discontinued. The trough value of gentamicin was
0.3 μg/mL (6.1 μmol/L) on days 8, 10, and 18. On day
33, the patient was discharged with a 14-day prescription
for oral ciprofloxacin (1600 mg/day [25 mg · kg-1 · day-1]).
Therefore, this patient was treated with gentamicin for
23 days, intravenous ciprofloxacin for 28 days, and oral
ciprofloxacin for 14 days. Subsequently, the identification
of the C. haemolyticum strain, MDA0585T, was confirmed,
based on its 16S rRNA gene sequence. Six months after
the accident, the patient was free of recurrent infection.
Discussion
Before the recognition of C. haemolyticum in 2011, less
than 140 proven cases of human infection with C.
violaceum had been reported [3]. Among the few reports
of infections caused by non-pigmented, β-hemolytic
strains of C. violaceum, identification of C. haemolyticum
strain MDA0585T by 16S rRNA gene sequencing has
not been previously reported. Thus, we present the first
clinical evidence for C. haemolyticum infection.
C. haemolyticum, strain MDA0585T, is a gram-negative
bacillus, and has been isolated from a clinical sample
[5] and from lake water [1]. C. violaceum and C.
haemolyticum are closely related, phylogenetically, making
them impossible to distinguish based on results of bio-
chemical tests (i.e., the Vitek GNI + card and the API
20 NE test). However, the lack of violet pigmentation,
hemolysis of sheep blood, and positive oxidase test
results allow an accurate identification. Hence, as shown
in the current report, these features can be used to dif-
ferentiate between these 2 bacterial species in a clinical
setting.
We have investigated the minimum inhibitory concen-
tration for C. haemolyticum. In addition, Han et al. showed
differences in the antibiotic susceptibility of C. haemo
lyticum and C. violaceum in clinical samples; hence, we
compared them and the results are shown in Table 1 [5].
C. haemolyticum was more resistant, overall, with higher
minimum inhibitory concentrations for most drugs. Thus,
the ability to differentiate between these 2 bacterial species
is important when infection with C. haemolyticum is
suspected because of its greater resistance to antimicro-
bials, especially the β-lactams [5].
In the present report, the patient was found to have
necrotizing fasciitis on day 6 based on his clinical pres-
entation. In terms of antibiotic therapy for necrotizing
fasciitis, currently acceptable regimens include the admin-
Figure 1 Clinical presentation on day 6.The patient experienced a
burning sensation, tenderness, and redness in his left leg, from the
upper part of his foot to his knee. Blisters are shown on the dorsum
of the foot.
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istration of a carbapenem or β-lactam/β-lactamase inhibi-
tor, together with clindamycin, in addition to an agent
with activity against methicillin-resistant S. aureus [6].
In addition, the Gram stain showed the bacteria to be
gram-negative. Hence, without the results of the blood
culture taken on day 4, we would likely have concluded
that the infection was caused by Burkholderia spp.,
Aeromonas spp., or Pseudomonas spp. [7], and would
have administrated antibiotics according to the therapy for
general necrotizing fasciitis. However, C. haemolyticum
Figure 2 Microbiological results. A. A large number of short, tapered, gram-negative bacilli were present in fasciotomy. (Gram stain, ×400
original magnification). B. Chromobacterium haemolyticum colonies, showing marked hemolysis on sheep blood agar after a 24-h culture.
Table 1 Growth, biochemical reactions, and results of antibiotic susceptibility tests for C. haemolyticum isolates
Present case Xan et al. [5]
Characteristic C. haemolyticum C. haemolyticum C. violaceum
Growth on agar (37°C, 5% CO2, 24 h): Non-pigmented Non-pigmented Purple
Sheep blood 2.3 mm, β-hemolysis 2 mm, β-hemolysis 2 mm, no hemolysis
Chocolate 2.9 mm 2 mm 2 mm
Buffered charcoal yeast extract NA 2 mm, flat, dull 2 mm, raised, shiny
Trypticase soy 2.9 mm 1.8 mm 1 mm
MacConkey NA 0.2 mm, pinpoint 1 mm
Hektoen enteric NA No growth 0.2 mm, pinpoint
Indole production (tryptophanase) - - +
Glucose fermentation NA + (weak) +
Utilization of:
Mannose - - +
Mannitol + + -
Citrate + + -
Oxidase + + -
Catalase - + (weak) +
Antimicrobial susceptibility (MIC,μg/mL)
Amikacin >32 16, S 3, S
Cefepime NA >32, R 2, S
Ceftriaxone NA >32, R >32, R
Ciprofloxacin <1 0.003, S 0.006, S
Imipenem 2 6.0, S 1.0, S
Penicillin NA >32, R >32, R
Piperacillin/tazobactam NA >256, R 3, S
Ticarcillin/clavulanate NA >256, R 32, I
Trimethoprim/sulfamethoxazole NA 0.094, S 0.094, S
MIC minimum inhibitory concentration, NA not assessed.
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has been found to be extremely resistant to beta-lactams.
Therefore, as our initial findings suggested an infection
with either C. haemolyticum or the closely related C.
violaceum, we provided long-term ciprofloxacin. According
to a study by Aldridge et al., ciprofloxacin was the most
active drug in combatting C. violaceum [8], and several
studies have reported successful treatment with this
therapy.
The most common symptoms of C. violaceum infections
are fever and pain over the infected site, in association
with various skin lesions [9]. To our knowledge, only 1
case of necrotizing fasciitis involving C. violaceum has
been reported [10]. According to the pathology results,
the patient in the current report had necrotizing fasciitis.
Chattopadhyay et al. have recommended aggressive de-
bridement for cases of C. violaceum infection [11].
Conclusions
C. haemolyticum should be considered in the differential
diagnosis of skin lesions that progressively worsen after
trauma involving exposure to river or lake water, even
in temperate regions. Second, early blood cultures for
isolation and identification are important for initiating
proper antimicrobial therapy.
Consent
Written informed consent was obtained from the patient
for publication of this case report and the accompanying
images. A copy of the written consent is available for
review by the Editor of this journal.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
MO, KS, YO, MN, TI, and AM contributed to patient management. MN and CK
performed the microbiological culturing and identification. MO and RI
drafted the initial manuscript. YO, MN, TI, and AM contributed to writing the
report. KS, SN, and NY critically reviewed the manuscript. All the authors
have provided written consent for publication. All authors read and
approved the final manuscript.
Acknowledgement
We would like to acknowledge Takako Sakamaki and Toshiko Ooishi for their
assistance, and Katsuhiko Hashimoto, Itaru Saito, Fumihito Ito, Yoshibumi
Kumada, and Hideyuki Yokoyama for their assistance with patient
management.
Author details
1Department of Emergency and Critical Care Medicine, Ohta Nishinouchi
Hospital, 2-5-20 Nishinouchi, 963-8558 Koriyama, Fukushima, Japan.
2Department of Emergency and Critical Care Medicine, The University of
Tokyo Hospital, 7-3-1 Hongo, 113-8655 Bunkyo-ku, Tokyo, Japan.
3Department of Emergency and Critical Care Medical Center, Fukushima
Medical University Hospital, 1 Hikariga-oka, 960-1295 Fukushima City, Japan.
4Department of Medicine, Ohta Nishinouchi Hospital, 2-5-20 Nishinouchi,
963-8558 Koriyama, Fukushima, Japan. 5Department of Bacteriology,
Fukushima Institute of Public Health, 16-6 Mitouchi, Houkida, Fukushima city,
Fukushima, Japan.
Received: 3 April 2013 Accepted: 28 August 2013
Published: 3 September 2013
References
1. Lima-Bittencourt CI, Costa PS, Barbosa FA, Chartone-Souza E, Nascimento
AM: Characterization of a Chromobacterium haemolyticum population
from a natural tropical lake. Lett Appl Microbiol 2011, 52:642–650.
2. Soby SD, Gadagkar SR, Contreras C, Caruso FL: Chromobacterium vaccinii
sp. nov. isolated from native and cultivated cranberry (Vaccinium
macrocarpon Ait.) bogs and irrigation ponds. Int J Syst Evol Microbiol 2012,
63:1840–1846.
3. Yang CH, Li YH: Chromobacterium violaceum infection: a clinical review of
an important but neglected infection. J Chin Med Assoc 2011, 74:435–441.
4. Sultan HY, Boyle AA, Sheppard N: Necrotising fasciitis. BMJ 2012,
345:e4274.
5. Han XY, Han FS, Segal J: Chromobacterium haemolyticum sp. nov., a
strongly haemolytic species. Int J Syst Evol Microbiol 2008, 58:1398–1403.
6. Mandell G, Bennett J, Dolin R: Mandell, Douglas, and Bennett’s Principles
and Practice of Infectious Diseases, 7th Edition. Philadelphia: Churchill
Livingston; 2010.
7. Campbell JI, Lan NP, Qui PT, Dung LT, Farrar JJ, Baker S: A successful
antimicrobial regime for Chromobacterium violaceum induced
bacteremia. BMC Infect Dis 2013, 13:4.
8. Aldridge KE, Valainis GT, Sanders CV: Comparison of the in vitro activity of
ciprofloxacin and 24 other antimicrobial agents against clinical strains of
Chromobacterium violaceum. Diagn Microbiol Infect Dis 1988, 10:31–39.
9. De Siqueira IC, Dias J, Ruf H, Ramos EA, Maciel EA, Rolim A, Labur L,
Vasconcelos L, Silvany C: Chromobacterium violaceum in siblings, Brazil.
Emerg Infect Dis 2005, 11:1443–1445.
10. Seigel JK, Stadler ME, Lombrano JL, Almony JS, Couch ME, Belhorn TH:
Chromobacterium violaceum necrotizing fasciitis: A case report and
review of the literature. Ear Nose Throat J 2012, 91:479–483.
11. Chattopadhyay A, Kumar V, Bhat N, Rao P: Chromobacterium violaceum
infection: A rare but frequently fatal disease. J Pediatr Surg 2002,
37:108–110.
doi:10.1186/1471-2334-13-406
Cite this article as: Okada et al.: Chromobacterium haemolyticum-
induced bacteremia in a healthy young man. BMC Infectious Diseases
2013 13:406.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Okada et al. BMC Infectious Diseases 2013, 13:406 Page 4 of 4
http://www.biomedcentral.com/1471-2334/13/406
